Companies / CytoDel
CytoDel
New York, United States
CytoDel is a preclinical stage biopharmaceutical company developing recombinant botulinum toxin derivatives that can deliver therapeutics to the neuronal cytoplasm
CytoDel, based in New York, United States, has 1 investor on file, among them Kairos Ventures. Its site was last checked 7 Nov 2026: site answers.
SEC Form D filings
2 filingsFiled by CytoDel, INC. with the SEC. A Form D reports a private offering; it is not a priced round.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
More from Kairos Ventures
23 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (41%), AI & Machine Learning (34%), Fintech (9%).
See Kairos Ventures' full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get CytoDel and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Kairos Ventures adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/cytodel.com/investors
# also
GET /v1/companies/cytodel.com
GET /v1/companies/cytodel.com/news